AAAAAA
Results: 1-25/31
Authors:
Schulman, S
Citation: S. Schulman, Differences in the rate of anticoagulant complications between routine practice and controlled prospective trials - Reply, J INTERN M, 250(3), 2001, pp. 260-261
Authors:
Barakat, LP
Smith-Whitley, K
Schulman, S
Rosenberg, D
Puri, R
Ohene-Frempong, K
Citation: Lp. Barakat et al., Nocturnal enuresis in pediatric sickle cell disease, J DEV BEH P, 22(5), 2001, pp. 300-305
Authors:
Schulman, S
Citation: S. Schulman, Study patients and routine practice patients, J INTERN M, 248(6), 2000, pp. 531-531
Authors:
Lindmarker, P
Schulman, S
Citation: P. Lindmarker et S. Schulman, The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg, J INTERN M, 247(5), 2000, pp. 601-606
Authors:
Millar, DS
Johansen, B
Berntorp, E
Minford, A
Bolton-Maggs, P
Wensley, R
Kakkar, V
Schulman, S
Torres, A
Bosch, N
Cooper, DN
Citation: Ds. Millar et al., Molecular genetic analysis of severe protein C deficiency, HUM GENET, 106(6), 2000, pp. 646-653
Authors:
Schulman, S
Citation: S. Schulman, Continuous infusion of recombinant factor VIIa in hemophilic patients withinhibitors: Safety, monitoring, and cost effectiveness, SEM THROMB, 26(4), 2000, pp. 421-424
Authors:
Schulman, S
Lindmarker, P
Citation: S. Schulman et P. Lindmarker, Venous thromboembolism and cancer. Reply, N ENG J MED, 343(18), 2000, pp. 1338-1338
Authors:
Schulman, S
Lindmarker, P
Citation: S. Schulman et P. Lindmarker, Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism, N ENG J MED, 342(26), 2000, pp. 1953-1958
Authors:
Schulman, S
Citation: S. Schulman, Inherited thrombophilia, THROMBOSIS AND ANTITHROMBOTIC THERAPY, 2000, pp. 21-35
Authors:
Schulman, S
Citation: S. Schulman, Acquired hypercoagulable states, THROMBOSIS AND ANTITHROMBOTIC THERAPY, 2000, pp. 37-51
Authors:
Schulman, S
Citation: S. Schulman, Direct, selective inhibitors of coagulation factors, THROMBOSIS AND ANTITHROMBOTIC THERAPY, 2000, pp. 145-156
Authors:
Schulman, S
Citation: S. Schulman, Prevention and treatment of venous thrombosis and pulmonary embolism, THROMBOSIS AND ANTITHROMBOTIC THERAPY, 2000, pp. 217-231
Authors:
Barzilai, A
Varon, D
Martinowitz, U
Heim, M
Schulman, S
Citation: A. Barzilai et al., Characteristics of septic arthritis in human immunodeficiency virus-infected haemophiliacs versus other risk groups, RHEUMATOLOG, 38(2), 1999, pp. 139-142
Authors:
Falk, G
Sui, GC
Schulman, S
Wiman, B
Citation: G. Falk et al., Detection of a new polymorphism in the PAI-1 gene located in the pro-peptide coding region, FIBRINOL PR, 13(1), 1999, pp. 26-30
Authors:
Schulman, S
Wallensten, R
White, B
Smith, OP
Citation: S. Schulman et al., Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery, HAEMOPHILIA, 5(2), 1999, pp. 96-100
Authors:
Berntorp, E
Ingerslev, J
Schulman, S
Citation: E. Berntorp et al., von Willebrand disease: an update in the Aland islands, HAEMOPHILIA, 5, 1999, pp. 1-6
Authors:
Schulman, S
Citation: S. Schulman, Haemostatic and replacement therapy in von Willebrand disease, HAEMOPHILIA, 5, 1999, pp. 57-59
Authors:
Schulman, S
Citation: S. Schulman, Oral anticoagulation - how intense and for how long?, J INTERN M, 245(4), 1999, pp. 365-368
Authors:
Schulman, S
Citation: S. Schulman, Oral anticoagulation in venous thromboembolism: decisions based on more than mere feelings, J INTERN M, 245(4), 1999, pp. 399-403
Authors:
Lindmarker, P
Schulman, S
Sten-Linder, M
Wiman, B
Egberg, N
Johnsson, H
Citation: P. Lindmarker et al., The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene, THROMB HAEM, 81(5), 1999, pp. 684-689
Authors:
Lubetsky, A
Schulman, S
Varon, D
Martinowitz, U
Kenet, G
Gitel, S
Inbal, A
Citation: A. Lubetsky et al., Safety and efficacy of continuous infusion of a combined factor VIII - vonWillebrand factor (vWF) concentrate (Haemate-P (TM)) in patients with von Willebrand disease, THROMB HAEM, 81(2), 1999, pp. 229-233
Authors:
Schulman, S
Buller, H
Citation: S. Schulman et H. Buller, Optimization of treatment for venous thromboembolism and prevention of recurrences - Co-chairman's summary, HAEMOSTASIS, 29, 1999, pp. 79-80
Authors:
Schulman, S
Citation: S. Schulman, For how long should the treatment with vitamin K antagonists be maintained?, HAEMOSTASIS, 29, 1999, pp. 89-90
Authors:
Astermark, J
Petrini, P
Tengborn, L
Schulman, S
Ljung, R
Berntorp, E
Citation: J. Astermark et al., Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized, BR J HAEM, 105(4), 1999, pp. 1109-1113
Authors:
van Gool, JD
Bloom, DA
Butler, RJ
Djurhuus, JC
Hjalmas, K
de Jong, TPVM
Kaplan, WE
Peters, CA
Podesta, ML
Amark, P
von Gontard, A
Hellstrom, AL
Rittig, S
Schulman, S
Vijverberg, M
Citation: Jd. Van Gool et al., Conservative management in children, INCONTINENCE, 1999, pp. 487-550